Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. News
  7. Summary
    HXL   AU0000111932

HEXIMA LIMITED

(HXL)
  Report
Delayed Quote. Delayed Australian Stock Exchange - 01/20 07:43:43 pm
0.39 AUD   -1.27%
01/03Hexima Appoints Commercial Chief
MT
01/03Phillip Rose Appoints Phillip Rose as Chief Commercial Officer
CI
2021HEXIMA : Notification regarding unquoted securities - HXL
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hexima Limited Updates Timeline to Phase 2B Results

01/06/2021 | 10:59pm EST

Hexima Limited developing HXP124, a new prescription treatment for onychomycosis, announced an updated timeline to delivery of results from its phase IIb clinical trial which is being conducted in patients with onychomycosis. The pace of enrolment of patients into the trial, which is being conducted in Australia and New Zealand, has been modestly impacted by State travel restrictions, business closures and mandated lock downs due to the Coronavirus pandemic. These events have not affected in any way the integrity of the trial but are likely to result in data from the clinical trial being available one calendar quarter later than previously anticipated. Hexima has recently added additional clinical investigator sites and adopted other measures to accelerate patient recruitment and enrolment. Accordingly, Hexima expects to announce results of its phase IIb clinical trial of HXP124 in patients with onychomycosis in the second quarter of 2022.


ę S&P Capital IQ 2021
All news about HEXIMA LIMITED
01/03Hexima Appoints Commercial Chief
MT
01/03Phillip Rose Appoints Phillip Rose as Chief Commercial Officer
CI
2021HEXIMA : Notification regarding unquoted securities - HXL
PU
2021HEXIMA : Notification regarding unquoted securities - HXL
PU
2021Hexima Names New Chief Development Officer
MT
2021HEXIMA : CEO's Presentation
PU
2021Hexima Limited Announces Cessation of Marilyn Anderson as Executive Director
CI
2021Hexima Limited Announces Appointment of Shari Lipner as Member of its Scientific Adviso..
CI
2021Hexima Limited Announces Appointment of Nancy Sacco as Chief Development Officer
CI
2021Hexima Completes Oversubscribed Share Purchase Plan
MT
More news
Financials
Sales 2022 - - -
Net income 2022 -9,30 M -6,70 M -6,70 M
Net cash 2022 41,5 M 29,9 M 29,9 M
P/E ratio 2022 -6,69x
Yield 2022 -
Capitalization 64,4 M 46,8 M 46,4 M
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees -
Free-Float 69,6%
Chart HEXIMA LIMITED
Duration : Period :
Hexima Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,39 AUD
Average target price 0,75 AUD
Spread / Average Target 92,3%
EPS Revisions
Managers and Directors
Michael Douglas Arthur Aldridge CEO, Non-Independent Non-Executive Director & MD
Jonathan West Non-Executive Chairman
Marilyn Ann Anderson Chief Scientific Officer
Yolanda Gaspar Head-Clinical Operations
Nicole Louise van der Weerden Director
Sector and Competitors
1st jan.Capi. (M$)
HEXIMA LIMITED-6.02%47
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831